Evolocumab

ApprovedTerminated

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Familial Hypercholesterolemia

Conditions

Familial Hypercholesterolemia

Trial Timeline

Nov 16, 2018 → Feb 4, 2020

NCT ID

NCT03331666

About Evolocumab

Evolocumab is a approved stage product being developed by Amgen for Familial Hypercholesterolemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT03331666. Target conditions include Familial Hypercholesterolemia.

What happened to similar drugs?

4 of 20 similar drugs in Familial Hypercholesterolemia were approved

Approved (4) Terminated (3) Active (14)

✅evolocumabAmgenApproved

✅AnakinraSwedish Orphan BiovitrumApproved

✅Colesevelam hydrochloride film-coated tablets + PlaceboSanofiApproved

✅PraluentSanofiApproved

🔄SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placeboJiangsu Hengrui MedicinePhase 3

🔄Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3

🔄rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calciumAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (17)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06140095	Phase 1	UNKNOWN	Feb 1, 2024	Dec 1, 2025	Acute Metabolic Effects of Evolocumab and Atorvastatin
NCT04539223	Approved	UNKNOWN	Aug 28, 2020	May 1, 2022	Carotid Artery Stenosis
NCT03944577	Phase 2	Completed	Jul 15, 2019	Mar 28, 2023	Heart Transplant
NCT03331666	Approved	Terminated	Nov 16, 2018	Feb 4, 2020	Familial Hypercholesterolemia
NCT03403374	Approved	Completed	Aug 4, 2018	Nov 27, 2019	Homozygous Familial Hypercholesterolemia HoFH
NCT03096288	Approved	Completed	Oct 3, 2017	Nov 2, 2020	Atherosclerotic Cardiovascular Disease
NCT03080935	Phase 3	Terminated	Mar 13, 2017	Mar 4, 2022	Dyslipidemia
NCT02957604	Pre-clinical	Terminated	Dec 22, 2016	Sep 2, 2020	Hypercholesterolemia; ASCVD; Pregnancy
NCT02624869	Phase 3	Completed	Sep 10, 2016	Jun 1, 2021	Familial Hypercholesterolemia
NCT02867813	Phase 3	Completed	Sep 2, 2016	Mar 21, 2022	Dyslipidemia
NCT02585895	Phase 3	Completed	Dec 21, 2015	Jan 20, 2017	Hypercholesterolemia
NCT02304484	Phase 3	Completed	Nov 24, 2014	Mar 9, 2018	Hypercholesterolemia
NCT02275156	Phase 1	Completed	Aug 19, 2014	Dec 19, 2014	Hyperlipidemia
NCT01652703	Phase 2	Completed	Jul 10, 2012	—	Hypercholesterolemia and High Risk for Cardiovascular Events
NCT01624142	Phase 2/3	Completed	Jun 1, 2012	May 11, 2018	Severe Familial Hypercholesterolemia
NCT01439880	Phase 2	Completed	Oct 7, 2011	Jun 20, 2018	Hypercholesterolemia
NCT01380730	Phase 2	Completed	Jul 1, 2011	Apr 5, 2012	Hyperlipidemia

Competing Products

20 competing products in Familial Hypercholesterolemia

See all competitors

Product	Company	Stage	Hype Score
Bromocriptine Mesilate + Placebos	Towa Pharmaceutical	Phase 1/2	32
SHR-1209	Jiangsu Hengrui Medicine	Phase 2	31
SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placebo	Jiangsu Hengrui Medicine	Phase 3	40
Rosuvastatin 20mg + Placebo	AstraZeneca	Phase 3	40
rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calcium	AstraZeneca	Phase 3	40
Rosuvastatin + Placebo	AstraZeneca	Phase 3	40
Rosuvastatin 20mg	AstraZeneca	Phase 3	40
AZD0780 + Placebo	AstraZeneca	Phase 3	44
Anacetrapib + Placebo for anacetrapib	Merck	Phase 3	40
Statins and Ezetimibe	Merck	Pre-clinical	22
Comparator: niacin (+) laropiprant (MK0524A) + Comparator: placebo	Merck	Phase 3	32
MK-0524A + MK-0524A	Merck	Phase 1	21
Enlicitide Decanoate + Placebo	Merck	Phase 2/3	45
Inclisiran + Placebo	Novartis	Phase 3	40
DFV890	Novartis	Phase 2	35
Canakinumab	Novartis	Phase 2	35
Inclisiran Sodium for injection + Placebo + Placebos	Novartis	Phase 3	40
LCQ908 + Placebo	Novartis	Phase 3	40
Inclisiran	Novartis	Phase 3	44
Inclisiran + Placebo	Novartis	Phase 3	40